Immunotec Announces Proposed Share Consolidation

Immunotec Inc. (TSX VENTURE:IMM) ("Immunotec" or the "Company") is pleased to
announce that at its Annual and Special Meeting of Shareholders (the "Meeting")
to be held on March 29, 2012, the Company will be seeking shareholder approval
of a special resolution authorizing an amendment to the Company's articles of
amalgamation on such basis as the directors of the Company may determine, so as
to consolidate its common shares (the "Common Shares") on the basis of one (1)
post-consolidation Common Share for a maximum fifteen (15) pre-consolidation
Common Shares (the "Share Consolidation"). In addition to approval from
Immunotec's shareholders by special resolution at the Meeting, the Share
Consolidation would also be subject to the approval of the TSX Venture Exchange.


The principal reasons for considering the Share Consolidation include the
Company's belief that, if approved and effected, the Company could benefit from
a raise of its share price to more attractive levels, the improvement of trading
liquidity and better chances of raising further capital in the future. The
change in the number of issued and outstanding Common Shares that would result
from the Share Consolidation would cause no change in the capital attributable
to the Common Shares and would not materially affect any shareholder's
percentage ownership in the Company, even though such ownership would be
represented by a smaller number of Common Shares. As at the date hereof, there
are an aggregate of 70,026,313 Common Shares issued and outstanding. If
approved, and should the Board of Directors elect to proceed to the Share
Consolidation on the basis of a 1:15 ratio, which ratio has not yet been
conclusively determined, upon completion of the Share Consolidation, there would
be an aggregate of approximately 4,668,421 Common Shares of the Company issued
and outstanding.


About Immunotec Inc.

Immunotec is a world class business opportunity supported by unique
scientifically proven products that improve wellness. Headquartered with
manufacturing facilities near Montreal, Canada, the Company also has
distribution capacities to support its commercial activities in Canada and
internationally to the United States, Europe, Mexico and The Caribbean.


The Company files its consolidated financial statements, its management and
discussion analysis report, its press releases and such other required documents
on the SEDAR database at www.sedar.com and on the Company's website at
www.immunotec.com. The common shares of the Company are listed on the TSX
Venture Exchange under the ticker symbol IMM. The TSX Venture does not accept
responsibility for the adequacy or accuracy of this release.


CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in
this news release are forward-looking and are subject to numerous risks and
uncertainties, known and unknown. For information identifying known risks and
uncertainties and other important factors that could cause actual results to
differ materially from those anticipated in the forward-looking statements,
please refer to the heading Risks and Uncertainties in Immunotec's most recent
Management's Discussion and Analysis, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated results
expressed in these forward-looking statements.